Diagnostic Innovations Driving Esoteric Testing Market Growth: Advancements in Melanoma and Preeclampsia Testing

Quest Diagnostics Introduces MelaNodal Predictâ„¢ for Personalized Melanoma Treatment

Quest Diagnostics, a prominent name in diagnostic information services, has unveiled MelaNodal Predictâ„¢, an innovative predictive gene expression test designed to tailor treatment decisions for melanoma patients. The test, which uses cutting edge technology produced in collaboration with SkylineDx and the Mayo Clinic, is currently available for order through Quest Diagnostics and Dermpath Diagnostics. 

MelaNodal Predictâ„¢ is a combination of tumor age and tumour density analysis with advanced gene expression profiling, which allows healthcare professionals to identify patients at different risk for nod metastasis. In addition, healthcare providers may prevent patients from unnecessarily invasive procedures such as sentinel lymph node biopsy by incorporating SkylineDx’s technology into Quest’s extensive expertise and nationwide coverage.

The launch of MelaNodal Predictâ„¢ marks a significant stride in personalized medicine for melanoma treatment, offering clinicians actionable insights to optimize patient care and outcomes.

Labcorp Introduces FDA-Cleared Blood Test for Severe Preeclampsia Risk Assessment

A new FDA cleared Blood Test to assess the risk of serious preeclampsia during pregnancy has been launched by Labcorp, a leading global provider of laboratory services. Developed by Thermo Fisher Scientific and recognized as one of TIME Magazine’s Best Inventions of 2023, the test measures two angiogenic biomarkers—sFlt-1 and PlGF—associated with preeclampsia.

The test, validated by a PRAECIS study involving over 1,000 pregnant women, has been shown to provide clinicians with a ratio of biomarkers that can help identify patients at risk for developing severe preeclampsia in 2 weeks. Pregnant women who test positive can benefit from enhanced surveillance and expedited care, mitigating potential complications.

Market Projection for Esoteric Testing

The market for Esoteric Testing is rapidly growing and is projected to reach USD 62.43 billion by 2032, up from USD 27.31 billion in 2023, with a CAGR of 10.89 %. This surge is driven by the to the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions. Moreover, strong financial resources from both public and private sectors coupled with continued technological progress are driving the market expansion. As the demand for advanced diagnostic solutions continues to soar, stakeholders anticipate sustained innovation and collaboration to address evolving healthcare needs effectively.

About Vantage Market Research:

We, at Vantage Market Research, provide
quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map
out constellation of opportunities for their businesses. We, as a competitive intelligence market research
and consulting firm provide end to end solutions to our client enterprises to meet their crucial business
objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high
quality data and market research services. The company serves various enterprises and clients in a wide
variety of industries. The company offers detailed reports on multiple industries including Chemical
Materials and Energy, Food and Beverages, Healthcare Technology, etc. The company’s experienced team of
Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and
techniques to gather and analyse information.